# Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
Canonical URL: https://biopharmsignal.com/news/ALKS/alkermes-to-present-additional-data-from-vibrance-1-phase-2-study-of-alixorexton-in-patients-with-narcolepsy-type-1-at-the-american-academy-of-neurology-aan-2026-annual-meeting
Ticker: ALKS
Company: Alkermes plc
Source: Alkermes plc
Published: 2026-04-16 11:00 EST
Original Source URL: https://investor.alkermes.com
## Summary

— Alixorexton Data From Seven-Week Open-Label Extension Period Demonstrated Sustained Improvements in Patient-Reported Disease Severity, Cognitive Functioning and Fatigue— — Alixorexton Was Generally Well Tolerated at All Doses Tested — — Phase 3 Brilliance NT1 Study of Alixorexton in Patients With

## Article Body
— Alixorexton Data From Seven-Week Open-Label Extension Period Demonstrated Sustained Improvements in Patient-Reported Disease Severity, Cognitive Functioning and Fatigue— — Alixorexton Was Generally Well Tolerated at All Doses Tested — — Phase 3 Brilliance NT1 Study of Alixorexton in Patients With
## Recent Company News
- 2026-06-04 11:00 EST — [Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research](https://biopharmsignal.com/news/ALKS/alkermes-to-present-new-data-on-alixorexton-and-lumryzr-sodium-oxybate-at-sleep-2026-highlighting-breadth-of-sleep-medicine-research) — Source: Alkermes plc
- 2026-06-03 20:05 EST — [Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/ALKS/alkermes-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-conference) — Source: Alkermes plc
- 2026-05-26 11:00 EST — [Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting](https://biopharmsignal.com/news/ALKS/alkermes-to-showcase-leadership-in-psychiatry-and-orexin-biology-with-new-data-at-the-american-society-of-clinical-psychopharmacology-annual-meeting) — Source: Alkermes plc
- 2026-05-21 11:00 EST — [Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences](https://biopharmsignal.com/news/ALKS/alkermes-showcases-data-from-psychiatry-portfolio-and-sleep-research-into-real-world-patient-experience-at-spring-2026-scientific-conferences) — Source: Alkermes plc
- 2026-05-12 11:00 EST — [Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia](https://biopharmsignal.com/news/ALKS/alkermes-announces-positive-topline-results-from-revitalyz-phase-3-study-evaluating-lumryzr-sodium-oxybate-extended-release-in-adults-with-idiopathic-hypersomnia) — Source: Alkermes plc
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)